Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Alentis Therapeutics

Request full access

Discovers and develops novel medications to treat advanced liver diseases

Allschwil, SwitzerlandFounded 2019Biotech & Life Sciences

About Alentis Therapeutics

Alentis Therapeutics is a clinical-stage biopharmaceutical company that operates in the healthcare sector, specifically in the development of treatments for cancer and fibrotic diseases. The company is based in Basel, Switzerland, with a subsidiary for research and development in Strasbourg, France.

The company's primary focus is on the development of first-in-class monoclonal antibodies against Claudin-1 (CLDN1). CLDN1 is a protein that plays a crucial role in the progression of diseases like cancer and fibrosis. When these diseases occur, the expression of CLDN1 increases and it moves outside of its usual location, the tight junctions between cells. This exposed, non-tight junctional CLDN1 drives the growth of cancer and fibrosis in various organs.

Alentis' lead products are monoclonal antibodies that specifically target this exposed and non-junctional CLDN1. In simple terms, these antibodies are designed to bind to the CLDN1 protein, thereby blocking its harmful effects and treating the disease.

The company's business model revolves around the research, development, and eventual commercialization of these treatments. Alentis serves a global market of patients suffering from cancers and fibrotic diseases, with a particular focus on those with a stiff, nonpermeable extracellular matrix (ECM) and immune-evasive tumor microenvironment.

In terms of revenue generation, Alentis is likely to earn income through the sale of its treatments once they have been approved for use by regulatory bodies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
69
Open positions
2
Dealroom signal
80.8/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Rumoured $1B, Biotech and Pharma, participations bpifrance, radar de l'innovation, observatoire industrial tech, proteomics, DT and LS, observatoire healthtech
Business model
Manufacturing
Client focus
B2B

Open roles

9 open roles
RoleTeamLocationPosted
Senior Director, Clinical Excellence LeadClinicalClinicalHamilton Applab, Switzerland1w ago
Chemist / Conjugation ExpertHamilton Applab, Switzerland +13w ago
Senior Director, Clinical Development OncologyClinicalClinicalHamilton Applab, Switzerland3w ago
Monoclonal Antibody Technical LeadHamilton Applab, Switzerland +13w ago
(Senior) Manager, CMC Program LeadHamilton Applab, Switzerland3w ago
Senior Clinical Trial Leader OncologyClinicalClinicalHamilton Applab, Switzerland3w ago
Senior Documentation SpecialistBasel, Switzerland1mo ago
Senior Documentation Specialist Alentis Therapeutics AG - Allschwil immediatelyHamilton Applab, Switzerland1mo ago
Contractor Senior Clinical Trial Manager (12 months)ClinicalClinicalAllschwil, Switzerland2mo ago
From job postings in the last four months. Careers page ↗More startups hiring →

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES DOther financing Nov 2024 $181M $726M Catalio Capital Management · Avego Bioscience Capital · Piper Heartland Healthcare Capital · Frazier Life Sciences ↗
SERIES COther financing Apr 2023 $105M $420M Bpifrance · Jeito Capital · Pureos Bioventures · Schroders Capital ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Alentis Therapeutics website traffic

Latest recorded traffic for Alentis Therapeutics is 5.3K monthly website visits, up 120.8% over the last three months. Alentis Therapeutics's team grew 1.5% over the past year.

Latest monthly visits5.3K 3-month web change+120.8% 1-year team growth+1.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Alentis Therapeutics in the Allschwil ecosystem

Live from Dealroom

The Alentis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

21 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

Series B and later9 investors entered at this stage

  • Novo Holdings
  • RA Capital Management
  • Schroders Capital
  • OrbiMed
  • Catalio Capital Management
  • Avego Bioscience Capital
  • Piper Heartland Healthcare Capital
  • Frazier Life Sciences
  • Longitude Capital

Other known investors5 additional known investors

  • BaseLaunch
  • INSERM
  • Institute of Image-Guided Surgery
  • SATT Conectus
  • University of Strasbourg
Team profiled 16 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Alentis Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.